Additionally, we have detailed the rationale and evidence supporting the application of select molecularly targeted radiosensitizers such as HSP90 inhibitors, tyrosine kinase inhibitors, and mTOR inhibitors in the treatment of prostate cancer. This evidence concerns the gene HSP90AA1 and Familial prostate cancer.